secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001104659-24-035297
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools exchanges all Series B Preferred for ~93M common shares
-------------------------------------------------------------------------

- Exchanged 127,780 Series B-1 and 127,779 Series B-2 shares for 92,930,553 common shares at $2.75 per share.
- Eliminated ~$250M liquidation preference and all Series B preferred governance rights, including change-in-control put.
- Incremental 17.8M shares issued vs. original $3.40 conversion price; dilution <5% on as-issued basis.
- Outstanding common shares now approx. 382.5M; no Series B shares remain after closing.
- Directors Eli Casdin and Fenel Eloi assigned to Class I (term 2026) and Class II (term 2024) respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000110465924035297/0001104659-24-035297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000110465924035297/tm249061d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-035297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer